{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:44:44Z","timestamp":1787024684257,"version":"build-2736575974"},"reference-count":24,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Cholangiocarcinoma is a rare type of cancer. Futibatinib is an irreversible, potent,\nselective inhibitor of fibroblast growth factor receptors (FGFR 1-4). On September\n30, 2022, the US FDA first approved futibatinib to treat adult patients with bile duct cancer\nwhose disease is unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma\nharboring fibroblast growth factor receptor 2 (FGFR2) gene mutations or other\nclasses of rearrangements. The approval of this medicine was based on phase 3 clinical\ntrial results including an overall response rate (ORR) of 42% and a duration of response\n(DoR) of 9.7 months. This short perspective summarizes Futibatinib\u2019s synthesis, physicochemical\nproperties, dosage, route of administration, mechanism of action, binding mode,\npharmacodynamics, pharmacokinetics, drug interactions, adverse events, and possible\nmechanism of resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867330666230416152913","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T16:08:00Z","timestamp":1681661280000},"page":"666-670","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth\nFactor Receptors for Treatment of the Bile Duct Cancer"],"prefix":"10.2174","volume":"31","author":[{"given":"Surya K.","family":"De","sequence":"first","affiliation":[{"name":"Department of Chemistry, Conju-Probe, San Diego, California, USA"},{"name":"Bharath University, Chennai, Tamil\nNadu, 600126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bpg.2015.02.003","volume":"29","author":"Bergquist A.","year":"2015","unstructured":"Bergquist A.; von Seth E.; Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015,29(2),221-232","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"Razumilava N.","year":"2014","unstructured":"Razumilava N.; Gores G.J.; Cholangiocarcinoma. Lancet 2014,383(9935),2168-2179","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4251\/wjgo.v2.i11.407","volume":"2","author":"Cardinale V.","year":"2010","unstructured":"Cardinale V.; Semeraro R.; Torrice A.; Gatto M.; Napoli C.; Bragazzi M.C.; Gentile R.; Alvaro D.; Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol 2010,2(11),407-416","journal-title":"World J Gastrointest Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.3748\/wjg.v10.i22.3374","volume":"10","author":"Liu C.","year":"2004","unstructured":"Liu C.; Wang J.; Ou Q.J.; Possible stem cell origin of human cholangiocarcinoma. World J Gastroenterol 2004,10(22),3374-3376","journal-title":"World J Gastroenterol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"Khan S.A.","year":"2019","unstructured":"Khan S.A.; Tavolari S.; Brandi G.; Cholangiocarcinoma: Epidemiology and risk factors. Liver Int 2019,39(S1)(Suppl. 1),19-31","journal-title":"Liver Int"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"Lowery M.A.","year":"2018","unstructured":"Lowery M.A.; Ptashkin R.; Jordan E.; Berger M.F.; Zehir A.; Capanu M.; Kemeny N.E.; O\u2019Reilly E.M.; El-Dika I.; Jarnagin W.R.; Harding J.J.; D\u2019Angelica M.I.; Cercek A.; Hechtman J.F.; Solit D.B.; Schultz N.; Hyman D.M.; Klimstra D.S.; Saltz L.B.; Abou-Alfa G.K.; Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. Clin Cancer Res 2018,24(17),4154-4161","journal-title":"Clin Cancer Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"Meric-Bernstam F.","year":"2022","unstructured":"Meric-Bernstam F.; Bahleda R.; Hierro C.; Sanson M.; Bridgewater J.; Arkenau H.T.; Tran B.; Kelley R.K.; Park J.O.; Javle M.; He Y.; Benhadji K.A.; Goyal L.; Futibatinib, an irreversible fgfr1\u20134 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: A phase I dose-expansion study. Cancer Discov 2022,12(2),402-415","journal-title":"Cancer Discov"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","volume":"80","author":"Sootome H.","year":"2020","unstructured":"Sootome H.; Fujita H.; Ito K.; Ochiiwa H.; Fujioka Y.; Ito K.; Miura A.; Sagara T.; Ito S.; Ohsawa H.; Otsuki S.; Funabashi K.; Yashiro M.; Matsuo K.; Yonekura K.; Hirai H.; Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res 2020,80(22),4986-4997","journal-title":"Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","volume":"31","author":"Bahleda R.","year":"2020","unstructured":"Bahleda R.; Meric-Bernstam F.; Goyal L.; Tran B.; He Y.; Yamamiya I.; Benhadji K.A.; Matos I.; Arkenau H.T.; Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1\u20134 inhibitor in patients with advanced solid tumors. Ann Oncol 2020,31(10),1405-1412","journal-title":"Ann Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13543784.2021.1837774","volume":"30","author":"Rizzo A.","year":"2021","unstructured":"Rizzo A.; Ricci A.D.; Brandi G.; Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives. Expert Opin Investig Drugs 2021,30(4),317-324","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMcpc2027092","volume":"384","author":"Goyal L.","year":"2021","unstructured":"Goyal L.; Chen C.T.; Pierce T.T.; Deshpande V.; Case 8-2021: A 34-year-old woman with cholangiocarcinoma. N Engl J Med 2021,384(11),1054-1064","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/cancers13071706","volume":"13","author":"Lee P.C.","year":"2021","unstructured":"Lee P.C.; Hendifar A.; Osipov A.; Cho M.; Li D.; Gong J.; Targeting the fibroblast growth factor receptor (fgfr) in advanced cholangiocarcinoma: Clinical trial progress and future considerations. Cancers 2021,13(7),1706","journal-title":"Cancers"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/cas.15486","volume":"114","author":"Doi T.","year":"2022","unstructured":"Doi T.; Shitara K.; Kojima T.; Kuboki Y.; Matsubara N.; Bando H.; Yoh K.; Naito Y.; Hirai H.; Kurokawa Y.; Kato T.; Morizane C.; Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci 2022,114(2),574-585","journal-title":"Cancer Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","volume":"40","author":"Chen L.","year":"2021","unstructured":"Chen L.; Zhang Y.; Yin L.; Cai B.; Huang P.; Li X.; Liang G.; Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges. J Exp Clin Cancer Res 2021,40(1),345","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=15","author":"Duan W.","year":"2017","unstructured":"Duan W.; Geng M.; Wang Y.; Ai J.; Fan J.; Dai Y.; Ding J.; New compound having fgfr inhibitory activity and preparation and application thereof. WO2017215485A1 2017"},{"key":"ref=16","author":"Sootome H.","year":"2015","unstructured":"Sootome H.;  Therapeutic agent for fgfr inhibitor-resistant cancer WO2015008844A 2015","journal-title":"Therapeutic agent for fgfr inhibitor-resistant cancer WO2015008844A"},{"key":"ref=17","author":"Sagara T.","year":"2013","unstructured":"Sagara T.; Ito S.; Otsuki S.; Sootome H.; 3,5-disubstituted alkynylbenzene compound and salt thereof. US9108973B2 2013"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s42004-021-00623-x","volume":"5","author":"Qu L.","year":"2022","unstructured":"Qu L.; Chen X.; Wei H.; Guo M.; Dai S.; Jiang L.; Li J.; Yue S.; Chen Z.; Chen Y.; Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Commun Chem 2022,5(1),5","journal-title":"Commun Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cpdd.1195","volume":"2","author":"Yamamiya I.","year":"2023","unstructured":"Yamamiya I.; Lester R.; Sonnichsen D.; Mina M.; He Y.; Benhadji K.A.; Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, qt\/qtc, phase 1 study in healthy subjects. Clin Pharmacol Drug Dev 2023,2(3),304-313","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"Goyal L.","year":"2019","unstructured":"Goyal L.; Shi L.; Liu L.Y.; Fece de la Cruz F.; Lennerz J.K.; Raghavan S.; Leschiner I.; Elagina L.; Siravegna G.; Ng R.W.S.; Vu P.; Patra K.C.; Saha S.K.; Uppot R.N.; Arellano R.; Reyes S.; Sagara T.; Otsuki S.; Nadres B.; Shahzade H.A.; Dey-Guha I.; Fetter I.J.; Baiev I.; Van Seventer E.E.; Murphy J.E.; Ferrone C.R.; Tanabe K.K.; Deshpande V.; Harding J.J.; Yaeger R.; Kelley R.K.; Bardelli A.; Iafrate A.J.; Hahn W.C.; Benes C.H.; Ting D.T.; Hirai H.; Getz G.; Juric D.; Zhu A.X.; Corcoran R.B.; Bardeesy N.; TAS-120 overcomes resistance to atp-competitive fgfr inhibitors in patients with fgfr2 fusion\u2013positive intrahepatic cholangiocarcinoma. Cancer Discov 2019,9(8),1064-1079","journal-title":"Cancer Discov"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/cmdc.201800719","volume":"14","author":"Kalyukina M.","year":"2019","unstructured":"Kalyukina M.; Yosaatmadja Y.; Middleditch M.J.; Patterson A.V.; Smaill J.B.; Squire C.J.; TAS-120 cancer target binding: Defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem 2019,14(4),494-500","journal-title":"ChemMedChem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"Lamarca A.","year":"2020","unstructured":"Lamarca A.; Barriuso J.; McNamara M.G.; Valle J.W.; Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol 2020,73(1),170-185","journal-title":"J Hepatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"106552","DOI":"10.1016\/j.phrs.2022.106552","volume":"187","author":"Roskoski R.","year":"2023","unstructured":"Roskoski R.; Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol Res 2023,187,106552","journal-title":"Pharmacol Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","volume":"27","author":"Vogel A.","year":"2023","unstructured":"Vogel A.; Segatto O.; Stenzinger A.; Saborowski A.; FGFR2 inhibition in cholangiocarcinoma. Annu Rev Med 2023,27(74),293-306","journal-title":"Annu Rev Med"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230416152913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215831\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230416152913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T10:19:02Z","timestamp":1699006742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215831\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230416152913","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}